Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects [PDF]
Clinical and Molecular Hepatology, 2021 Hepatocellular carcinoma (HCC) is usually accompanied by chronic liver damage, which sometimes influences the selection of HCC treatment. The Barcelona Clinic Liver Cancer (BCLC) staging system, which was first introduced in 1999, is the most commonly ...
Takuji Torimura, Hideki Iwamoto
doaj +1 more source
Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study [PDF]
Journal of Liver Cancer, 2023 Background/Aim To evaluate the applicability of transarterial chemoembolization (TACE) treatment with doxorubicin drug-eluting beads (DEBs) in advanced hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI).
Su Jong Yu +7 more
doaj +1 more source
Hepatocellular carcinoma with Budd-Chiari syndrome due to membranous obstruction of the inferior vena cava with long-term follow-up: a case report [PDF]
Journal of Liver Cancer, 2022 Membranous obstruction of the inferior vena cava (MOVC) is a rare subset of Budd-Chiari syndrome (BCS) with a subacute onset that is often complicated by cirrhosis and hepatocellular carcinoma (HCC).
Choong Hee Kim +9 more
doaj +1 more source
JGH Open, 2023 Background and Aim Transcatheter arterial chemoembolization (TACE) using various anticancer drugs is often performed to treat hepatocellular carcinoma (HCC).
Hironobu Ihira +12 more
doaj +1 more source
The Korean Journal of Gastroenterology, 2020 Background/Aims: A switch to systemic therapy, such as sorafenib, should be considered for hepatocellular carcinoma (HCC) patients refractory to transarterial chemoembolization (TACE).
Kang Hyun Park +10 more
doaj +1 more source
c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis
Hepatology, EarlyView., 2022 In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie +17 more
wiley +1 more source
Ultraselective conventional transarterial chemoembolization: When and how? [PDF]
Clinical and Molecular Hepatology, 2019 Ultraselective conventional transarterial chemoembolization (cTACE), defined as cTACE at the most distal portion of the subsubsegmental hepatic artery, is mainly performed for hepatocellular carcinoma (HCC) ≤5 cm.
Shiro Miyayama
doaj +1 more source
PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma [PDF]
Journal of Experimental & Clinical Cancer Research, 2020 Abstract Background Therapeutic options for patients with hepatocellular carcinoma (HCC) are limited. Transarterial chemoembolization (TACE) is an interventional procedure used to deliver chemotherapy and embolizing agents directly to the tumor and is the procedure of choice for patients with intermediate stage HCC.
Sean P. Martin +8 more
openaire +3 more sources
Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization [PDF]
The Korean Journal of Internal Medicine, 2019 Background/Aims Transarterial chemoembolization (TACE) is performed for single hepatocellular carcinoma (HCC) that are not eligible for surgery or ablation therapy.
Min Young Baek +14 more
doaj +1 more source
Technology in Cancer Research & Treatment, 2022 Introduction: This retrospective study aimed to compare the efficacy and safety of transarterial chemoembolization plus lenvatinib and programmed death 1 (PD-1) inhibitors versus transarterial chemoembolization plus lenvatinib or sorafenib in patients ...
Shu Zhao MD +6 more
doaj +1 more source